Alixia

What Alixia does

Alixia is a privately held, early-stage biotechnology company founded in 2022 and headquartered in San Francisco, with incorporation in Delaware. Per its public description, the company engages in medical research aimed at developing new therapeutic modalities to treat cancer, aging, and inflammation — three broad but distinct therapeutic verticals that imply a multi-indication research pipeline rather than a single-asset focus. The team is small (1-10 employees) and is led by co-founder and co-CEO Helen Chen alongside founder Olof Mollstedt, with no further management detail disclosed.

The company's business model is not commercially articulated in the available data: no products, services, pricing, partnerships, customers, or revenue streams are disclosed. Alixia has funded itself to date through venture capital, beginning with a $500,000 seed round in March 2022 led by Y Combinator with Eight Capital and Gaingels participating, followed in 2024 by an ongoing SEC-registered exempt securities offering (Form D) targeting approximately $3.47 million, of which roughly $1.83 million has been sold, with ZAKA VC identified as a participating investor. As a preclinical biotech with no disclosed pipeline assets, modalities, or research milestones, Alixia's near-term operating posture is consistent with capital-funded discovery research rather than commercial revenue generation.

Name

Alixia

Legal name

Alixia, Inc.

Website

https://alixia.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Alixia is a preclinical, privately held biotechnology company founded in 2022 and based in San Francisco that researches new therapeutic modalities to treat cancer, aging, and inflammation, funded to date by Y Combinator, Gaingels, Eight Capital, and ZAKA VC.

Ownership category

akta.pro rank

Product category

Biotechnology Research

akta.pro primary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

Keywords

• Biotechnology research
• Cancer therapeutics
• Anti-aging treatments
• Inflammation therapeutics
• Drug discovery

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Alixia, Inc. is a privately held biotechnology research company engaged in developing new therapeutic modalities to treat cancer, aging, and inflammation. The company is incorporated in Delaware and headquartered in San Francisco, California, and operates at an early research stage without commercially launched products, services, or named pipeline assets disclosed in the source data. The current operating focus is on raising capital via exempt securities offerings to fund ongoing R&D activities.

Product overview

Alixia, Inc. is a biotechnology company incorporated in Delaware and based in San Francisco. According to the available source data, no specific products, services, or product modules were identified in the provided sources. The company is engaged in an exempt securities offering as reported in its SEC Form D filing.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Calico Labs: Alphabet-backed life sciences company focused on aging biology and longevity therapeutics. Comparable to Alixia given shared focus on aging as a therapeutic indication, though Calico operates at vastly greater scale and capitalization.
• Altos Labs: Well-capitalized biotechnology company developing cellular rejuvenation programming to treat aging and age-related diseases. Directly comparable therapeutic focus (aging) but with substantially larger funding base and operational footprint than Alixia.

Direct peers

• Unity Biotechnology: Clinical-stage biotechnology company developing senolytic therapeutics to treat aging-related diseases including inflammatory and ophthalmologic conditions. Closely comparable in therapeutic area (aging and inflammation) and modality innovation profile.
• Recursion Pharmaceuticals: AI-driven biotechnology company combining automated wet-lab experimentation with machine learning to discover novel therapeutics across multiple indications including cancer and inflammation. Comparable in using new modalities/approaches to drug discovery in overlapping therapeutic areas.
• NewLimit: Biotechnology company developing epigenetic reprogramming therapies to treat aging and age-related disease. Directly comparable in therapeutic focus (aging) and modality innovation, with similar early-stage private profile to Alixia.

Emerging players

• Insitro: Machine learning-driven drug discovery company applying AI to predict drug behavior and design novel therapeutics. Comparable as a next-generation modality/biotech startup leveraging technology to address therapeutic areas overlapping with Alixia's focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alixia